Robert Warne

1.5k total citations
16 papers, 1.0k citations indexed

About

Robert Warne is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Robert Warne has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in Robert Warne's work include Mast cells and histamine (3 papers), Peptidase Inhibition and Analysis (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Robert Warne is often cited by papers focused on Mast cells and histamine (3 papers), Peptidase Inhibition and Analysis (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Robert Warne collaborates with scholars based in United States, Switzerland and South Korea. Robert Warne's co-authors include Gregory A. Brent, David D. Moore, John W. Harney, P. Reed Larsen, Ronald J. Koenig, P. Reed Larsen, James M. Clark, William R. Moore, Alejandro Cortes and Cindy Fishman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Robert Warne

15 papers receiving 995 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Warne United States	12	512	461	360	171	120	16	1.0k
Caroline Pendaries France	10	485 0.9×	189 0.4×	312 0.9×	123 0.7×	64 0.5×	12	950
W R Baumbach United States	19	671 1.3×	818 1.8×	292 0.8×	107 0.6×	117 1.0×	31	1.5k
Marie‐Thérèse Groyer‐Picard France	15	419 0.8×	175 0.4×	394 1.1×	162 0.9×	50 0.4×	20	1.1k
Guy Fayet France	16	368 0.7×	275 0.6×	160 0.4×	49 0.3×	100 0.8×	26	802
Yasunori Yokota Japan	16	573 1.1×	59 0.1×	144 0.4×	204 1.2×	114 0.9×	19	956
Nabil Moghrabi United States	15	470 0.9×	187 0.4×	313 0.9×	165 1.0×	92 0.8×	27	1.1k
Beverly K. Jones United States	18	1.1k 2.1×	154 0.3×	515 1.4×	263 1.5×	48 0.4×	23	1.6k
Tomio Kotani Japan	18	355 0.7×	592 1.3×	126 0.3×	166 1.0×	113 0.9×	39	965
Dietmar von der Ahe Germany	15	782 1.5×	104 0.2×	446 1.2×	200 1.2×	52 0.4×	19	1.3k
Gemma Rodríguez‐Tarduchy Spain	12	652 1.3×	119 0.3×	78 0.2×	334 2.0×	51 0.4×	16	1.1k

Countries citing papers authored by Robert Warne

Since Specialization

Citations

This map shows the geographic impact of Robert Warne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Warne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Warne more than expected).

Fields of papers citing papers by Robert Warne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Warne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Warne. The network helps show where Robert Warne may publish in the future.

Co-authorship network of co-authors of Robert Warne

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Warne. A scholar is included among the top collaborators of Robert Warne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Warne. Robert Warne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Daemen, Anneleen, Natalie Yuen, Xi Chen, et al.. (2025). Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors. Cancer Research. 85(8_Supplement_1). 452–452.

Long, Jason E., Soochan Kim, Ha Yeong Kim, et al.. (2022). Abstract 3335: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models. Cancer Research. 82(12_Supplement). 3335–3335. 4 indexed citations

Junttila, Melissa R., Arghya Ray, Robert Warne, et al.. (2022). CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma. Blood. 140(Supplement 1). 9957–9958. 2 indexed citations

Junttila, Melissa R., Arghya Ray, Robert Warne, et al.. (2022). Abstract 2074: ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma. Cancer Research. 82(12_Supplement). 2074–2074. 5 indexed citations

Ma, Xiaolei, Lili Xie, Charles Wartchow, et al.. (2017). Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit. Scientific Reports. 7(1). 9385–9385. 20 indexed citations

Lu, Yipin, Mark Knapp, Kenneth Crawford, et al.. (2017). Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors. Journal of Molecular Biology. 429(11). 1684–1704. 28 indexed citations

Xie, Lili, Charles Wartchow, Steven Shia, et al.. (2015). Molecular Basis of mRNA Cap Recognition by Influenza B Polymerase PB2 Subunit. Journal of Biological Chemistry. 291(1). 363–370. 19 indexed citations

Warne, Robert, Xueshi Hao, Dirksen E. Bussiere, et al.. (2010). Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorganic & Medicinal Chemistry Letters. 20(13). 3897–3902. 27 indexed citations

Rice, Kenneth D., Anthony R. Gangloff, Elaine Y. Kuo, et al.. (2000). Dibasic inhibitors of human mast cell tryptase. Part 1: Synthesis and optimization of a novel class of inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(20). 2357–2360. 25 indexed citations

10.

Janc, James W., James M. Clark, Robert Warne, et al.. (2000). A Novel Approach to Serine Protease Inhibition: Kinetic Characterization of Inhibitors Whose Potencies and Selectivities Are Dramatically Enhanced by Zinc(II). Biochemistry. 39(16). 4792–4800. 27 indexed citations

11.

Clark, James M., W M Abraham, Cindy Fishman, et al.. (1995). Tryptase Inhibitors Block Allergen-Induced Airway and Inflammatory Responses in Allergic Sheep. American Journal of Respiratory and Critical Care Medicine. 152(6). 2076–2083. 164 indexed citations

12.

Tanaka, Richard D., James M. Clark, Robert Warne, William M. Abraham, & William R. Moore. (1995). Mast Cell Tryptase: A New Target for Therapeutic Intervention in Asthma. International Archives of Allergy and Immunology. 107(1-3). 408–409. 23 indexed citations

13.

Mandel, S. J., Marla J. Berry, J. David Kieffer, et al.. (1992). Cloning and in vitro expression of the human selenoprotein, type I iodothyronine deiodinase.. The Journal of Clinical Endocrinology & Metabolism. 75(4). 1133–1139. 103 indexed citations

14.

Brent, Gregory A., et al.. (1989). Mutations of the Rat Growth Hormone Promoter which Increase and Decrease Response to Thyroid Hormone Define a Consensus Thyroid Hormone Response Element. Molecular Endocrinology. 3(12). 1996–2004. 221 indexed citations

15.

Koenig, Ronald J., Robert Warne, Gregory A. Brent, et al.. (1988). Isolation of a cDNA clone encoding a biologically active thyroid hormone receptor.. Proceedings of the National Academy of Sciences. 85(14). 5031–5035. 205 indexed citations

16.

Koenig, Ronald J., Gregory A. Brent, Robert Warne, P. Reed Larsen, & David D. Moore. (1987). Thyroid hormone receptor binds to a site in the rat growth hormone promoter required for induction by thyroid hormone.. Proceedings of the National Academy of Sciences. 84(16). 5670–5674. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact